Loading
companiesCompany
Clarity Pharmaceuticals
Clarity Pharmaceuticals, a Sydney radiopharmaceutical company, pairs copper isotopes with SAR-bisPSMA, a molecule that binds PSMA on prostate cancer cells: copper-64 for PET imaging, in the phase 3 AMPLIFY and CLARIFY trials, and copper-67 for therapy in the SECuRE trial. The copper-67 therapy is still at the dose-finding stage.
Overview
Co-PSMA head-to-head data (EAU 2026) showed Cu-64 SAR-bisPSMA more than doubled lesion and patient detection versus Ga-68 PSMA-11; FDA Fast Track in biochemical recurrence; commercial manufacturing agreement with Nucleus RadioPharma (April 2026). SECuRE therapy trial: 7 of 19 patients at 8 GBq 67Cu reached complete response or undetectable disease (July 2026).
Similar pages
- Key paperProstate-specific membrane antigen expression in normal and malignant human tissues
Shares Theranostics, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- PairingPSMA PET → PSMA radioligand therapy
Shares Theranostics, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- PersonJeremie Calais
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- PersonJohannes Czernin
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- PersonPeter Bartenstein
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- TreatmentLocametz (kit for Ga-68 gozetotide)
Shares Theranostics, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- PersonLouise Emmett
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- Key paper[ 177 Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Shares Theranostics, PSMA, PSMA PET, Radioligand therapy (beta emitters).
cancers
fronts
technologies
targets
terms
trials
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate CancerPositron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy